Prasugrel: A new antiplatelet drug for the prevention and treatment of cardiovascular disease

Cardiology in Review

Volumn 16, Issue 6, 2008, Pages 314-318

  Koo, Michael H ^a   Nawarskas, James J ^b   Frishman, William H ^c,d  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antiplatelet agents; Cardiovascular disease; P2Y12 inhibition; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; EFFIENT; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ARTERY DISEASE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE TIME EFFECT RELATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; HEART INFARCTION; HUMAN; ISCHEMIA; LIVER FUNCTION; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; DOSE RESPONSE; RISK FACTOR;

CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THIOPHENES; TICLOPIDINE;

EID: 58149312852     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318189a701     Document Type: Review

References (54)

1. Savi P, Laplace MC, Maffrand JP, et al. Binding of [3H]-2-methylthio ADP to rat platelets: effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther. 1994;269:772-777.
2. Savi P, Labouret C, Delesque N, et al. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun. 2001; 283:379-383.
3. Hashimoto M, Sugidachi A, Isobe T, et al. The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel. Biochem Pharmacol. 2007;74:1003-1009.
4. Lerner RG, Frishman WH, Mohan KT. Clopidogrel: a new antiplatelet drug. Heart Dis. 2000;2:168-173.
5. CAPRIE Steering Committee. A randomized, blinded, trial of clopi-dogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
6. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation. 1998; 98:1597-1603.
7. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998;98:2126- 2132.
8. Cutlip DE, Leon MB, Ho KK, et al. Acute and nine month clinical outcomes after "suboptimal" coronary stenting: results from the STent Anti-thrombotic Regimen Study (STARS) registry. J Am Coll Cardiol. 1999;34:698-706.
9. Mehta SR, Yusuf S, Peters RJ, et al. Effect of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
10. Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med. 2002;252:233-238.
11. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreat-ment platelet reactivity. Circulation. 2003;107:2908-2913.
12. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, uns-elected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-2564.
13. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171- 3175.
14. Seerebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246-251.
15. Wenaweser P, Dorffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol. 2005;45:1748-1752.
16. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003;91:1123-1125.
17. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Heamost. 2003;89:783-787.
18. Nguyen T, Frishman WH, Nawarskas J, et al. Variability of response to clopidogrel: possible mechanisms and clinical implications. Cardiol in Rev. 2006;14:136-142.
19. Zeidner JF, Frishman WH, Lerner RG. Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease. Cardiol in Rev. 2008;16:250-259.
20. Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129:1439-1446.
21. Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylester-ases 1 and 2. Drug Metab Dispos. 2008;36:1227-1232.
22. Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992;44:527-532.
23. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30: 1288-1295.
24. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53-59.
25. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891-896.
26. Ding Z, Kim S, Dorsam RT, et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood. 2003;101:3908-3914.
27. th Meeting of the Japanese Society forthe Study of Xenobiotics Program, October 23-27, 2005.
28. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;34:600-607.
29. Payne CD, Brandt JT, Weerakkody G, et al. Superior inhibition of platelet aggregation following a loading dose of CS747 (prasugrel, LY640315) versus clopidogrel: correlation with the pharmacokinetics of active metabolite generation. J Thromb Haemost. 2005;3(Suppl 1): P0952.
30. Jakubowski JA, Payne CD, Brandt JT, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006;47:377-384.
31. Asai F, Jakubowski JA, Naganuma H, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets. 2006;17:209-217.
32. Matsushima N, Jakubowski JA, Asai F, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans. Platelets. 2006;17:218-226.
33. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J. 2004;25:166-181.
34. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl):234S-264S.
35. Jakubowski J, Winters KJ, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25:357-374.
36. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007; 153:e9-e16.
37. Jakubowski JA, Payne CD, Weerakkody GJ, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol. 2007;49:167-173.
38. Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol. 2007;63:421-430.
39. Cahill RA, McGreal GT, Crowe BH, et al. Duration of increased bleeding tendency after cessation of aspirin therapy. J Am Coll Surg. 2005;200:564-573.
40. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166-1173.
41. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation. 2007;116: 2923-2932.
42. Müller C, Büttner HJ, Petersen J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after placement of coronary-artery stents. Circulation. 2000;101:593-690.
43. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
44. Lange RA, Hillis LD. Antiplatelet therapy for ischemic heart disease. N Engl J Med. 2004;350:277-280.
45. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol. 2002;40:231-237.
46. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111:3366 -3373.
47. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thromboly-sis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627-635.
48. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopi-dogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
49. Murphy S, Antman E, Wiviott S, et al; for the TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasug-rel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J. 2008;August 21 [epub ahead of print].
50. Wiviott SD, Braunwald E, Horvath I, et al. Intensive oral antiplatelet therapy improves ischaemic outcomes in patients with acute coronary syndromes undergoing percutaneous coronary intervention with stenting regardless of stent type: the TRITON-TIMI 38 coronary stent analysis: a subanalysis of a randomized trial. Lancet. 2008;371:1353-1363.
51. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med. 2007;347:2078-2081.
52. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822- 1834.
53. Anonymous. New Prasugrel Head-to-Head Phase III Study Against Clopidogrel. Press release issued in the U.S. on November 4, 2007. Available at: http://www.daiichisankyo.com/4less/cgi-bin/cs4view-obj.php/ b-newsrelease-n1-eng/382/071104v2-e.pdf. Accessed August 5, 2008.
54. Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J. 2008;156(Suppl 1):S16-S22.